imported 2024-03-17 17:43:08
Gérard Mangoua dresse un bilan du secteur de la distribution de médicaments en Afrique, et nous parle des défis qu’il doit surmonter en tant que Directeur Général d’Ubipharm et PDG de Planet Pharma, mais aussi de ses avantages concurrentiels. Il évoque également ses priorités du moment et partage sa vision pour le futur du secteur et de ses activités.
Gérard Mangoua, Directeur Général d’Ubipharm et PDG de Planet Pharma, explique quels sont ses avantages concurrentiels par rapport à d’autres acteurs de la distribution de médicaments.
Ibrahim Diawara explique comment le secteur pharmaceutique s’est développé au cours des deux dernières années en Côte d’Ivoire et évoque la nécessité de mettre en place une politique protectionniste. Il parle également des dernières réalisations de Cipharm et partage sa vision pour le futur.
Ibrahim Diawara, Président Directeur Général de Cipharm, explique quelles ont été les réalisations majeures du groupe ces dernières années, ainsi que les avantages concurrentiels de Cipharm sur le marché pharmaceutique en Côte d’Ivoire.
Abdullahi Ali, Chairman and CEO of Simba Investments and Member of the Somalia National Alliance Party (SNAP), talks about investments and gives an overview of Kenya and Somalia.
It’s very clear that the family business in Saudi Arabia is dominant in general for the economy. The future of the family business has to be improved and developed to meet the challenges, which is technology and many other things.
Khalid Abdul-Latif Youssef is executive manager of Jamjoom Pharma talks about the pharmaceutical industry in Saudi Arabia and Jamjoom Pharma — one of the leading pharmaceutical companies in Saudi Arabia.
In addition, according to Ninth Development Plan by Ministry of Economic & Planning, increasing life expectancy (74 years) which is leading to an ageing population in need for specific and costly health services (> 60 years are growing from 4% to 7% in 2020).
Our group has been in the pharma industry for more than 25 years. We have been quite successful. We have partners who have contributed a lot to the pharma industry. In 2014, our turnover was almost SAR 2 billion. Recently we realized there was a need in the market, and among our partners, for local manufacturing.
Jamjoom Medicine was established more than 55 years ago. It has been one of the major players in the healthcare industry. Jamjoom Medicine was the first member of the Jamjoom Pharmaceutical Group. Our strategy to preserve and improve the market leadership has always been built around establishing a successful partnership with our suppliers, through mutual business respect, understanding and a focus on customers’ needs.
